Referral patterns and adjuvant chemotherapy use in patients with stage II colon cancer

Clinical Colorectal Cancer

Volumn 9, Issue 3, 2010, Pages 150-156

  Kirkpatrick, Haskell ^a   Aitelli, Cristi ^a   Qin, Huanying ^b   Becerra, Carlos ^a   Lichliter, Warren ^c   McCollum, A David ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Center for Spine Care   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bowel obstruction; Comorbidity; Patient selection; T stage

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER REGISTRY; CANCER STAGING; COLON CANCER; COLON RESECTION; COMORBIDITY; FEMALE; HEALTH INSURANCE; HUMAN; INSURANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PATIENT REFERRAL; PREDICTOR VARIABLE; TUMOR DIFFERENTIATION; UNITED STATES; COLONIC NEOPLASMS; MIDDLE AGED; PATHOLOGY; REGISTER; STATISTICS AND NUMERICAL DATA; UTILIZATION;

AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; REFERRAL AND CONSULTATION; REGISTRIES;

EID: 77954946604     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2010.n.020     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) database [Web site]. Available at: http://seer.cancer.gov/statfacts/html/ colorect. html. Accessed: June 15, 2009.
3. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322:352-358
4. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-2351
5. Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004; 22:3395-3407
6. Benson AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer. J Clin Oncol 2004; 22:3408-3419
7. Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002; 20:3999-4005.
8. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-383
9. Colon cancer. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-v.1.2008. National Comprehensive Cancer Network [Web site]. Available at: http://www.nccn.org/professionals/physician-gls/PDF/colon. pdf. Accessed: June 15, 2009.
10. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005; 23:8671-8678
11. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999; 17:1356-1363
12. Kuebler JP, Wieand S, O'Connel MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25:2198-2204
13. Compton C, Fenoglio-Preiser CM, Pettigrew N, et al. American Joint Committee on Cancer Prognostic Factors Consensus Conference. Cancer 2000; 88: 1739-1757
14. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96:1420-1425
15. Gill S, Loprinzi DJ, Sargent SD, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22:1797-1806
16. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. NEngl J Med 2001; 345:1091-1097
17. Des Guetz G, Schischmanoff O, Nicolas P, et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer 2009; 45:1890-1896
18. Quah HM, Schrag JD, Shia J, et al. Young age influences treatment but not outcome of colon cancer. Ann Surg Oncol 2007; 14:2759-2765
19. Earle CC, Neumann PJ, Gelber RD, et al. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol 2002; 20:1786-1792
20. Steyerberg EW, Neville B, Weeks JC, et al. referral patterns, treatment choices, and outcomes in locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol 2007; 25:2389-2396
21. Neugut AI, Grann VR. Referral to medical oncologists: are there barriers at the gate? J Clin Oncol 2002; 20:1716-1718
22. Siminoff LA, Zhang A, Saunders Sturm CM, et al. Referral of breast cancer patients to medical oncologists after initial surgical management. Med Care 2000; 38:696-704.
23. Watanabe T, Wu TT, Catalano PJ, et al. Molecular Predictors of Survival after Adjuvant Chemotherapy for colon cancer. N Engl J Med 2001; 344:1196-1206
24. Barrier A, Boelle PY, Roser F, et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 2006; 24:4685-4691.